Articles by Louis Garguilo
-
A Trait For Quailty In John McKay's DNA
9/24/2014
If you string together some of John McKay’s qualifications, they form what looks something like a strand of DNA from a new life form: CMQCQAQMS. And this particular gene would express a single trait: McKay knows quality like few others.
-
Serial Entrepreneur Points To Initial Funding Sources For Biotechs
9/24/2014
Kevin Judice lists himself on LinkedIn as “Entrepreneur.” Perhaps he has to; there just isn’t enough space to include the three companies he recently started and at which he concurrently is employed as CEO or CSO.
-
Lean Six Sigma From An Outsourcing Industry Raconteur
8/29/2014
Bikash Chatterjee knows all about Lean Six Sigma. He’ll share that wisdom with us at Outsourced Pharma West in San Francisco, November 11-12. However, you might not notice when he’s doing it.
-
A Witness To The History of Outsourcing
8/21/2014
Joe Guiles seems too young and mild-mannered to have been at the outbreak of a revolution that began many years ago. But he witnessed firsthand the inception of what would become the complete penetrability of outsourcing throughout the drug industry.
-
Big Pharma Veteran, Peter Bigelow, Will Help “Tell It Like It Is” At Outsourced Pharma West
8/18/2014
Peter Bigelow is both excited and motivated for Outsourced Pharma West in San Francisco November 10-11, by the targeted subject (drug development and manufacturing outsourcing) and streamlined format (all panelist and attendee discussion; no presentations).
-
When To Invest In Protein Production: The Risk-Reward Calculation
8/12/2014
A message to biotech start-ups, scientist-entrepreneurs and life sciences organizations banking on your exciting protein-based drug-discovery programs and technologies: When it comes to the timing of your investment, if you don’t pay now, you might pay (much) more later.
-
Learn Pfizer’s Guiding Principles For Externalization At Outsourced Pharma West
8/4/2014
Firelli Alonso-Caplen has been managing outsourcing for 10 years, first at Wyeth and then Pfizer. “The key really is the initial selection process for the CDMO,” she said in a recent conversation regarding our panel at Outsourced Pharma West, in San Francisco, November 10-11.
-
ONO Pharmaceutical Strives For Global Sales
7/31/2014
Gyo Sagara, president, representative director and CEO, challenges his company to enter the cancer field and gain big-pharma relevance.
-
Sanofi-Genzyme Together On CMO Reputation Management
Not long after Sanofi tied the knot with Genzyme in 2011, Piet Houwen was asked to lead contract-manufacturing operations. Now about 5 years into the marriage, I visit with Houwen to learn about this combination of Big Pharma and Big Bio, his role, and an attitudinal adjustment for better biologics outsourcing.
-
Quality, Capacity And Job Security In A CMO Industry Merger -- Part 2 Of Our Interview With CEO Of Newly Formed DPx Holdings B.V.
This spring Jim Mullen became CEO of DPx Holdings B.V., formed in a $2.65 billion transaction combining JLL Partners’ assets Patheon and Banner Life Sciences, with Royal DSM’s Pharmaceuticals business. In an interview with Outsourced Pharma, Mullen discusses three key components in a merger: quality, capacity and job security.
With a merger nearing completion and the integration plans underway, Mullen says you have to start with the fundamental ABCs of business. “There are three fundamental questions to get to day one: Do you have the right financial controls? Can you reliably continue to pay your suppliers? Can you receive cash and can you make payroll?